Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER

An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related...

Full description

Bibliographic Details

Published in:	Ophthalmology (Rochester, Minn.) Vol. 128; no. 7; p. 1050
Main Authors:	Monés, Jordi, Srivastava, Sunil K, Jaffe, Glenn J, Tadayoni, Ramin, Albini, Thomas A, Kaiser, Peter K, Holz, Frank G, Korobelnik, Jean-Francois, Kim, Ivana K, Pruente, Christian, Murray, Timothy G, Heier, Jeffrey S
Format:	Journal Article
Language:	English
Published:	United States 01.07.2021
Subjects:	neovascular age-related macular degeneration intraocular inflammation safety brolucizumab retinal vasculitis retinal arterial occlusion retinal occlusive vasculitis retinal vascular occlusion
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!